|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.270 USD | -0.91% |
|
-4.11% | -5.76% |
| 08/05 | Prime Medicine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| 17/04 | Prime Medicine, Inc. Appoints Svetlana Makhni as Chief Financial Officer | CI |
Business description: Prime Medicine, Inc.
Number of employees: 146
Sales by Activity: Prime Medicine, Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Biotechnology (Startups) | - | - | - | 2.98M | 4.63M |
Geographical breakdown of sales: Prime Medicine, Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | - | - | - | 2.98M | 4.63M |
Executive Committee: Prime Medicine, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
Allan Reine
CEO | Chief Executive Officer | 51 | 19/05/2025 |
Andrew Anzalone
PRN | Corporate Officer/Principal | 39 | 13/09/2019 |
Svetlana Makhni
DFI | Director of Finance/CFO | 42 | 16/04/2026 |
| Chief Operating Officer | 54 | 01/09/2022 | |
Ann Lee
CTO | Chief Tech/Sci/R&D Officer | 64 | 01/10/2021 |
Composition of the Board of Directors: Prime Medicine, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
Robert Nelsen
BRD | Director/Board Member | 62 | 01/09/2020 |
David Schenkein
BRD | Director/Board Member | 68 | 13/09/2019 |
Wendy Chung
BRD | Director/Board Member | 57 | 01/11/2021 |
| Director/Board Member | 66 | 01/12/2021 | |
Michael Kelly
BRD | Director/Board Member | 69 | 01/11/2021 |
Thomas Cahill
BRD | Director/Board Member | 39 | 01/11/2021 |
Jeffrey Marrazzo
CHM | Chairman | 48 | 19/05/2025 |
Allan Reine
BRD | Director/Board Member | 51 | 17/01/2024 |
Company details: Prime Medicine, Inc.
Bio Therapeutic Drugs
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.91% | -4.11% | +157.48% | -74.29% | 596M | |
| -1.58% | -0.17% | +40.62% | +85.63% | 50.91B | |
| -1.28% | -0.07% | +81.96% | +64.48% | 49.21B | |
| +1.72% | -13.93% | +79.56% | +529.95% | 25.14B | |
| -1.53% | -3.18% | -2.40% | -12.36% | 23.69B | |
| -2.13% | -0.48% | +39.16% | -28.39% | 17.81B | |
| -1.66% | -4.83% | +32.60% | -41.30% | 16.5B | |
| -2.59% | -9.79% | +51.89% | +196.19% | 15.3B | |
| -0.84% | +5.27% | -23.65% | +992.44% | 14.71B | |
| -2.39% | -3.74% | +39.85% | - | 13.73B | |
| Average | -1.37% | -1.62% | +49.71% | +190.26% | 22.76B | |
| Weighted average by Cap. | -1.29% | -1.87% | +45.55% | +172.69% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- PRME Stock
- Company Prime Medicine, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition